An FXR agonist, obeticholic acid (OCA), was recently approved by the FDA for treatment of patients with PBC who did not respond adequately to ursodeoxycholic acid (UDCA), the only drug approved previously (3, 4, 19). The gene discussed is NR1H4; the disease is primary biliary cholangitis.